March 2026: A Science Day has been scheduled in the federal GLP-1 litigation involving NAION claims
doi: 10.1074/jbc.M414548200
Disclosures: Prashanth Thevkar Nagesh: Nothing to Disclose, Yuan Zhuang: Nothing to Disclose, Mrigya Babuta: Nothing to Disclose, Marti Ortega-Ribera: Nothing to Disclose, the AlcHepNet clinical investigators: Nothing to Disclose, Gyongyi Szabo: CYTA Therapeutics: Consultant, Durect Corporation: Consultant, Merck: Consultant, Pandion Therapeutics: Consultant, Pfizer: Consultant, Terra Firma: Consultant, LabCorp: Consultant, Takeda: Consultant, Surrozen: Advisor, Intercept: Advisor, Evive: Advisor, Glympse Bio, Inc (acquired by Sunbird Bio): Advisor, Satellite Biosciences: Advisor, Zomagen Bioscience/Ventyx Biosciences: Consultant, Springer Nature Group: Royalties or patent beneficiary, UpToDate Inc: Royalties or patent beneficiary 1540 ELEVATED SYSTEMIC IGM ANTIBODIES TARGETING MALONDIALDEHYDE ADDUCTS PROMOTE ALCOHOL-ASSOCIATED LIVER DISEASE VIA COMPLEMENT ACTIVATION Dragana Raji 1 Beatriz Silva 1 Benedikt Simbrunner 2 Benedikt Hofer 1 Constanze Hoebinger 1 Nikolina Papac-Milicevic 1 Mattias Mandorfer 2 Thomas Reiberger 2 Tim Hendrikx 2 , 1 Medical University Vienna, 2 Medical University of Vienna Background: Alcohol- associated liver disease (ALD) associates with elevated immunoglobulin type M (IgM) levels in circulation
and Grade 1: hypothyroidism and optic neuropathy, n = 1 each)
If you have significant diabetes or weight-related health issues, the benefits to your health might outweigh the small theoretical risks
